Gene association with HLA suggests involvement of immune mediated mechanisms in the pathogenesis of Parkinson's disease (PD). Only a small number of studies have found differences between circulating leukocyte populations in PD patients compared to controls, with conflicting results. To clarify whether there is a circulating leukocyte PD phenotype, we assessed the numbers of T, B and natural killer cells, and monocytes and found a small reduction (15-25%) in CD4+ T and CD19+ B cells in PD. These findings suggest some compromise in immune cells in PD and have potential implications for immune function and the progression of PD.
Introduction
Parkinson's disease (PD) is the most common neurodegenerative movement disorder and recent genome-wide association studies (GWAS) have shown an increased risk for PD with variation in the HLA (human leukocyte antigen) region of chromosome 6 (Hamza et al., 2010; Do et al., 2011; Nalls et al., 2011; Simon-Sanchez et al., 2011) . This region contains a number of genes involved in inflammation and immunosurveillance, strongly supporting an involvement of the immune system in the pathogenesis of PD. In addition, large studies show that regular long-term use of the anti-inflammatory drug ibuprofen significantly reduces the risk of developing PD (Samii et al., 2009; Gagne and Power, 2010; Gao et al., 2011) . Of the variants identified, a strong association has been found within a region of HLA that encodes the major histocompatibility complex Class II receptor, HLA-DR (Hamza et al., 2010) . This cell surface receptor is expressed on antigen presenting cells such as microglia, and increased numbers of HLA-DR positive microglia have been found in close proximity to dead or dying neurons in affected brain regions in PD (McGeer et al., 1988; Imamura et al., 2003) . HLA-DR also interacts with receptors on T lymphocytes and both CD4+ and CD8+ T lymphocytes have been identified post-mortem in the brains of PD patients (McGeer et al., 1988; Brochard et al., 2009) . Studies in animal models clearly demonstrate a role for T lymphocytes in the development and progression of PD (Benner et al., 2008; Cao et al., 2011) . The involvement of the immune system in PD pathogenesis suggests that populations of circulating blood leukocytes may also differ between PD patients and controls.
There have been a small number of studies assessing changes in circulating leukocyte populations in PD patients with conflicting results. In PD, CD4+ T helper cells are reported as both unchanged and decreased (Chiba et al., 1995; Bas et al., 2001; Hisanaga et al., 2001; Baba et al., 2005; Niwa et al., 2012) , CD8+ cytotoxic T cells are reported as both unchanged and increased (Chiba et al., 1995; Bas et al., 2001; Hisanaga et al., 2001; Baba et al., 2005) and B cells are reported as decreased in PD compared to controls using both CD19+ (Bas et al., 2001 ) and CD20+ activation markers (Niwa et al., 2012) . To our knowledge, circulating CD3-CD56+ natural killer and TCRγδ cells have only been examined in single papers with the authors reporting an increase in both cell types (Fiszer et al., 1994b; Mihara et al., 2008) , and CD14+ monocytes have not been examined in this disease. In order to verify these findings and resolve any discrepancies, this study has assessed the major populations of circulating blood leukocytes in a cohort of PD patients and controls to determine whether there is a typical PD phenotype.
Material and methods

Subjects
Eighty-eight (56 male, 32 female) PD patients were recruited for this study with informed consent. All PD patients had a tremor-dominant phenotype and were levodopa responsive. No patient or control subject had a haematological, immune or inflammatory disorder, or was taking Journal of Neuroimmunology 252 (2012) [95] [96] [97] [98] [99] 
